

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 943 683 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

22.09.1999 Bulletin 1999/38

(21) Application number: 98203620.4

(22) Date of filing: 27.10.1998

(51) Int. Cl.<sup>6</sup>: **C12N 15/12**, C12N 15/11,  
C12N 15/85, C12N 5/10,  
C07K 14/705, C12Q 1/68,  
G01N 33/50, A61K 31/70

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 10.03.1998 GB 9805137

20.07.1998 GB 9815791

03.09.1998 GB 9819278

(71) Applicant:

SMITHKLINE BEECHAM PLC  
Brentford, Middlesex TW8 9EP (GB)

(72) Inventors:

- Duckworth, David M.  
SmithKline Beecham Pharm.  
Harlow, Essex CM19 5AW (GB)

• Davis, John B.

SmithKline Beecham Pharm.  
Harlow, Essex CM19 5AW (GB)

• Meadows, Helen J.

SmithKline Beecham Pharm.  
Harlow, Essex CM19 5AW (GB)

• Hayes, Philip D.

SmithKline Beecham Pharm.  
Harlow, Essex CM19 5AW (GB)

(74) Representative:

Connell, Anthony Christopher et al  
SmithKline Beecham plc  
Corporate Intellectual Property,  
Two New Horizons Court  
Brentford, Middlesex TW8 9EP (GB)

(54) **Human vanilloid receptor homologue Vanilrep1**

(57) VANILREP1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing VANILREP1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

EP 0 943 683 A1

## Description

### Field of the Invention

5 [0001] This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

### Background of the Invention

10 [0002] The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

15 [0003] Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterize further genes and their related polypeptides/proteins, as targets for drug discovery.

### Summary of the Invention

20 [0004] The present invention relates to VANILREP1, in particular VANILREP1 polypeptides and VANILREP1 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of pain, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algisia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and inflammatory disorders hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with VANILREP1 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate VANILREP1 activity or levels.

### Description of the Invention

35 [0005] In a first aspect, the present invention relates to VANILREP1 polypeptides. These include the polypeptide of SEQ ID NO:2 and polymorphic variants thereof, for example PVP-1, the polypeptide of SEQ ID NO:8. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 90% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to that of SEQ ID NO:2 or SEQ ID NO:8 over the entire length of SEQ ID NO:2 or SEQ ID NO:8 respectively. Such polypeptides include those comprising the amino acid of SEQ ID NO:2 or SEQ ID NO:8.

40 [0006] Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 90% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, over the entire length of SEQ ID NO:2 or SEQ ID NO:8. Such polypeptides include the polypeptide of SEQ ID NO:2 and SEQ ID NO:8.

45 [0007] Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1 or SEQ ID NO:7.

[0008] Polypeptides of the present invention are believed to be members of the ion channel family of polypeptides. They are therefore of interest because they are associated with the mechanism of action of capsaicin (a vanilloid compound), a constituent of chilli peppers. Capsaicin elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. The channels are permeable to cations and exhibit a notable preference for divalent cations, particularly calcium ions. The level of calcium ion permeability exceeds that observed for most non-selective cation channels and is similar to values observed for NMDA-type glutamate receptors and alpha7 nicotinic acetylcholine receptors, both of which are noted for this property. These properties are hereinafter referred to as VANILREP1 activity" or VANILREP1 polypeptide activity" or "biological activity of VANILREP1". Also included amongst these activities are antigenic and immunogenic activities of said VANILREP1 polypeptides, in particular the antigenic and immunogenic activities of the polypeptides of SEQ ID NO:2 or SEQ ID NO:8. Preferably, a polypeptide of the present invention exhibits at least one biological activity of VANILREP1.

[0009] The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger

protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, prosequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

**[0010]** The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

**[0011]** Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

**[0012]** In a further aspect, the present invention relates to VANILREP1 polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 90% identity, preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, over the entire length of SEQ ID NO:2 or SEQ ID NO:8, respectively. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:7, encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:8, respectively.

**[0013]** Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:8, respectively, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

**[0014]** Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, to SEQ ID NO:1 or SEQ ID NO:7, over the entire length of SEQ ID NO:1 or SEQ ID NO:7, respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:7, as well as the polynucleotide of SEQ ID NO:1 and SEQ ID NO:7, respectively.

**[0015]** The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

**[0016]** The nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:7 show homology with rat vanilloid receptor VR1 (M. J. Caterina et al., Nature 389:816-824, 1997). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 864 to 3380) encoding a polypeptide of 839 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is structurally related to other proteins of the ion channel family, having homology and/or structural similarity with rat vanilloid receptor VR1 (M. J. Caterina et al., Nature 389: 816-824, 1997).

**[0017]** The nucleotide sequence of SEQ ID NO:7 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 864 to 3380) encoding a polypeptide of 839 amino acids, the polypeptide of SEQ ID NO:8. The nucleotide sequence encoding the polypeptide of SEQ ID NO:8 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:7 or it may be a sequence other than the one contained in SEQ ID NO:7, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:8. The polypeptide of the SEQ ID NO:8 is structurally related to other proteins of the ion channel family, having homology and/or structural similarity with rat vanilloid receptor VR1 (M. J. Caterina et al., Nature 389: 816-824, 1997).

**[0018]** Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one VANILREP1 activity.

**[0019]** The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:2 and SEQ ID NO:8.

**[0020]** Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

(a) comprises a nucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, yet more preferably at least 97-99% identity to SEQ ID NO:3 or SEQ ID NO:5, over the entire length of SEQ ID NO:3 or SEQ ID NO:5, respectively;

(b) has a nucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, yet more preferably at least 97-99% identity, to SEQ ID NO:3 or SEQ ID NO:5, over the entire length of SEQ ID NO:3 or SEQ ID NO:5, respectively;

(c) the polynucleotide of SEQ ID NO:3 or SEQ ID NO:5; or

(d) a nucleotide sequence encoding a polypeptide which has at least 90% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively;

as well as the polynucleotides of SEQ ID NO:3 and SEQ ID NO:5.

**[0021]** The present invention further provides for a polypeptide which:

(a) comprises an amino acid sequence which has at least 90% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to that of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively;

(b) has an amino acid sequence which has at least 90% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively;

(c) comprises the amino acid of SEQ ID NO:4 or SEQ ID NO:6; and

(d) is the polypeptide of SEQ ID NO:4 or SEQ ID NO:6;

as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3 or SEQ ID NO:5.

**[0022]** The nucleotide sequences of SEQ ID NO:3 and SEQ ID NO:5, and the peptide sequences encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognized by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. *et al.*, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequences of SEQ ID NO:3 and SEQ ID NO:5, and the peptide sequence encoded therefrom, are therefore subject to the same inherent limitations in sequence accuracy.

**[0023]** Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain, cerebellum, dorsal root ganglia, thymus, leukocytes, placenta, foetal liver spleen and ovary, using the expressed sequence tag (EST) analysis (Adams, M.D., *et al.* Science (1991) 252:1651-1656; Adams, M.D. *et al.*, Nature, (1992) 355:632-634; Adams, M.D., *et al.*, Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

**[0024]** When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

**[0025]** Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, respectively and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

**[0026]** Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:7, respectively, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1 or SEQ ID NO:7. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

[0027] A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:7, respectively or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:7, or a fragment thereof.

[0028] The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

[0029] There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

[0030] Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

[0031] For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al, Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

[0032] Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

[0033] A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

[0034] If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the

screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

**[0035]** Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

**[0036]** This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 or SEQ ID NO:7, respectively which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

**[0037]** Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled VANILREP1 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising VANILREP1 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

**[0038]** The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the VANILREP1 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

**[0039]** Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:7, respectively or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:8, respectively or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2 or SEQ ID NO:8, respectively.

**[0040]** It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly pain, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and inflammatory disorders, amongst others.

**[0041]** The nucleotide sequences of the present invention are also valuable for chromosome localisation. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins Univer-

sity Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

[0042] The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

[0043] The gene of the present invention maps to human chromosome 17p13. The nucleotide sequences of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the human VANILREP1 polypeptides in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, for example PCR. Such techniques are well known in the art. Results from these studies provide an indication of the normal functions of the polypeptides in the organism. In addition, comparative studies of the normal expression pattern of human VANILREP1 mRNAs with that of mRNAs encoded by a human VANILREP1 gene provide valuable insights into the role of mutant human VANILREP1 polypeptides, or that of inappropriate expression of normal human VANILREP1 polypeptides, in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

[0044] The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

[0045] Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

[0046] Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

[0047] The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

[0048] Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

[0049] In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

[0050] Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

[0051] A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately

prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

**[0052]** Polypeptides of the present invention are responsible for one or more biological functions, including one or more disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirable to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

**[0053]** The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring VANILREP1 activity in the mixture, and comparing the VANILREP1 activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and VANILREP1 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

**[0054]** The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

**[0055]** The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

**[0056]** Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

**[0057]** Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

- (a) a polypeptide of the present invention;
  - (b) a recombinant cell expressing a polypeptide of the present invention;
  - (c) a cell membrane expressing a polypeptide of the present invention; or
  - (d) antibody to a polypeptide of the present invention;
- which polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:8.

**[0058]** It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

**[0059]** It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:



- (a) determining in the first instance the three-dimensional structure of the polypeptide;
- (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;
- (c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
- (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.

It will be further appreciated that this will normally be an iterative process.

**[0060]** In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, pain, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and inflammatory disorders, related to either an excess of, or an under-expression of, VANILREP1 polypeptide activity.

**[0061]** If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the VANILREP1 polypeptide.

**[0062]** In still another approach, expression of the gene encoding endogenous VANILREP1 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices ("triplexes") with the gene can be supplied (see, for example, Lee *et al.*, Nucleic Acids Res (1979) 6:3073; Cooney *et al.*, Science (1988) 241:456; Dervan *et al.*, Science (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*. Synthetic antisense or triplex oligonucleotides may comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesised with these or other modified backbones also form part of the present invention.

**[0063]** In addition, expression of the human VANILREP1 polypeptide may be prevented by using ribozymes specific to the human VANILREP1 mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave human VANILREP1 mRNAs at selected positions thereby preventing translation of the human VANILREP1 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

**[0064]** For treating abnormal conditions related to an under-expression of VANILREP1 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of VANILREP1 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

**[0065]** In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers

filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

[0066] The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

[0067] The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

[0068] Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

[0069] Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as those in the GCG and Lasergene software packages. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 or SEQ ID NO:7 and/or a polypeptide sequence encoded thereby.

[0070] The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

[0071] "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

[0072] "Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

[0073] "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

[0074] "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-

translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

**[0075]** "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

**[0076]** "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. *et al.*, *J. Molec. Biol.* 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., *et al.*, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., *et al.*, *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

**[0077]** Preferred parameters for polypeptide sequence comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Nat. Acad. Sci. USA.* 89:10915-10919 (1992)  
Gap Penalty: 12  
Gap Length Penalty: 4

**[0078]** A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

**[0079]** Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: matches = +10, mismatch = 0  
Gap Penalty: 50  
Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

[0080] By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \circ y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

[0081] Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \circ y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

[0082] "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

[0083] "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

[0084] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

**Example****Example 1 - Electrophysiological Studies**

5 [0085] *Xenopus laevis* oocyte removal and dissociation were performed. Injections of cDNA for **VANILREP1** were made into the nuclei of defolliculated oocytes (1.5ng cDNA/oocyte). After injection the oocytes were incubated between 19-22°C in modified Barth's solution (MBS) plus gentamycin (0.1mg/ml, pH 7.4) and used for electrophysiological recordings within 2-4 days.

10 [0086] For electrophysiological recordings oocytes were placed in a recording chamber and continuously perfused with a solution containing in mM: NaCl 88, KCl 1, NaHCO<sub>3</sub> 2.4, HEPES 15, MgCl<sub>2</sub> 1, BaCl<sub>2</sub> 0.1. (14 ml min<sup>-1</sup>). Solution was applied using large bore tubing (internal diameter 1.5mm) which facilitated rapid solution exchange (half-time 350 - 1000 ms). Oocytes were held under voltage clamp at -60m V using the two-electrode voltage-clamp technique. Electrodes were low resistance (0.5-3 MΩ) and were filled with 3 M KCl.

15 [0087] Currents were evoked in response to application of capsaicin applied through the perfusion system until the maximum current amplitude was reached. Figure 1 shows currents evoked from a cell in response to capsaicin over a range of concentrations. Figure 2 shows inhibition of the capsaicin evoked response (1 μM) by capsazepine (10 μM). The inhibition is reversible with extended washing.

20

25

30

35

40

45

50

55

## SEQUENCE INFORMATION

SEQ ID NO:1

5 CAGCGTCGGGTGCAGTTTGGCCGGAGGTTGCAGTGAGCAGAGATTGCCCCATTGCACTCT  
 AGTCTGGGCGACAGGGTGAGACACACACACACACACACACACACACACACACAC  
 ACACAAGCCTAAACATTCTCAGGCCAGGATGCTTGACAGATGTTGATTTCATAAAAAATGACA  
 AAAAGCACAAAATCCAAAATCTCGTATAAGCTCAGTGCGTGTGGCAGCGAGGTTGAAGAG  
 10 CAAAGGCAGGCCGGGCACCTGGCTGATGATGTGTGGACCCGTTGCACAGCAGGGCCCCGC  
 AGTGCAGGTGTGGGTGTGGGTGTGGGTGGGCCAGTYTCTGCCGCTCACCTATTCCAGGGA  
 CACAGTCTGCTTGGCTCTTCTGGACTGAGCCATCCTCATCACCGAGATCCTCCCTGAATT  
 CAGCCCACGACAGCCACCCCGGCCGTTTTCTTGTCTGTGTGGGGAGGGAGGCAGCGCG  
 15 GTGGTTATCAACCTCACCTGCAGAGGAGGCACCTGAGGCCAGAGACGAGGAGGGATGG  
 GTCTAACCCAGAACCACAGATGGCTCTGAGCCGGGGCCTGTCCACCCTCCCAGGCCGAC  
 GTCAGTGGCCGAGGACTGCCTGGGCCCTGCTAGGCCCTGCTCACCTCTGAGGCCCTCTGGG  
 GTGAGAGGTTCACTCCTGGAAACACTTCAGTTCTAGGGGGCTGGGGGCAGCAGCAAGTTG  
 GAGTTTTGGGGTACCCTGCTTCACAGGGCCCTTGGCAAGGAGGGCAGGTGGGGTCTAAGG  
 20 ACAAGCAGTCCCTTACTTTGGGAGTCAACCCCGCGTGGTGGCTGCTGCAGGTTGCACACT  
 GGGCCACAGAGGATCCAGCAAGGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTG  
 CGGACCCACTCCAAAAGGACACCTGCCCAGACCCCTGGATGGAGACCCTAACTCCAGGC  
 CACCTCCAGCCAAGCCCCAGCTCTCCACGGCCAAGAGCCGACCCGGCTCTTTGGGAAGG  
 25 GTGACTCGGAGGAGGCTTTCCCGGTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCT  
 GCCCCACCATCACAGTCAGCCCTGTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCG  
 GTGCCAGGTGCTGTCCCAGGACTCTGTGCGCCGAGCACCAGAGAAGACCCTCAGGCTCT  
 ATGATCGCAGGAGTATCTTTGAAGCCGTTGCTCAGAATAACTGCCAGGATCTGGAGAGCC  
 30 TGCTGCTCTTCTGTCAGAAGAGCAAGAAGCACCTCACAGACAACGAGTTCAAAGACCCTG  
 AGACAGGGAAGACCTGTCTGCTGAAAGCCATGCTCAACCTGCACGACGGACAGAACACCA  
 CCATCCCCCTGCTCCTGGAGATCGCGCGGCAACCGGACAGCCTGAAGGAGCTTGTCAACG  
 CCAGCTACACGGACAGCTACTACAAGGGCCAGACAGCACTGCACATCGCCATCGAGAGAC  
 35 GCAACATGGCCCTGGTGACCCTCCTGGTGGAGAACGGAGCAGACGTTCCAGGCTGCGGCCC  
 ATGGGGACTTCTTTAAGAAAACCAAAGGGCGGCCTGGATTCTACTTCGGTGAAGTGCCTCC  
 TGTCCCTGGCCGCGTGCACCAACCAGCTGGGCATCGTGAAGTTCTGCTGCAGAACTCCT  
 GGCAGACGGCCGACATCAGCGCCAGGACTCGGTGGGCAACACGGTGTGTCACGCCCTGG  
 40 TGGAGGTGGCCGACAACACGGCCGACAACACGAAGTTTGTGACGAGCATGTACAATGAGA  
 TTCTGATCCTGGGGGCCAACTGCACCCGACGCTGAAGCTGGAGGAGCTCACCACAAGA  
 AGGGAATGACGCCGCTGGCTCTGGCAGCTGGGACCGGGAAGATCGGGGTCTTGGCCTATA  
 TTCTCCAGCGGGAGATCCAGGAGCCCGAGTGCAGGCACCTGTCCAGGAAGTTACCGAGT  
 45 GGGCCTACGGGCGCGTGCACCTCCTCGCTGTACGACCTGTCTGTCATCGACACCTGCGAGA  
 AGAACTCGGTGCTGGAGGTGATCGCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACA  
 TGCTCTTGGTGGAGCCGCTGAACCGACTCCTGCAGGACAAGTGGGACAGATTCGTCAAGC  
 GCATCTTCTACTTCAACTTCTGGTCTACTGCCTGTACATGATCATCTTACCATGGCTG  
 50 CCTACTACAGGCGCGTGGATGGCTTGCCCTCCCTTTAAGATGGAAAAAACTGGAGACTATT  
 TCCGAGTTACTGGAGAGATCCTGTCTGTGTTAGGAGGAGTCTACTTCTTTTTCCGAGGGA  
 TTCAGTATTTCTTCTGTCAGAGGCGGCCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTG  
 AGATGCTTTTCTTCTGTCAGTCACTGTTTCATGCTGGCCACCGTGGTGTGACTTCAGCC  
 55

ACCTCAAGGAGTATGTGGCTTCCATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGC  
TCTACTACACCCGCGGTTTCCAGCAGATGGGCATCTATGCCGTCATGATAGAGAAGATGA  
5 TCCTGAGAGACCTGTGCCGTTTTCATGTTTGTCTACATCGTCTTCTTGTTCCGGGTTTTCCA  
CAGCGGTGGTGACGCTGATTGAAGACGGGAAGAATGACTCCCTGCCGTCTGAGTCCACGT  
CGCACAGGTGGCGGGGGCCTGCCTGCAGGCCCCCGATAGCTCCTACAACAGCCTGTACT  
CCACCTGCCTGGAGCTGTTCAAGTTCACCATCGGCATGGGCGACCTGGAGTTCAGTGA  
10 ACTATGACTTCAAGGCTGTCTTCATCATCTGTGCTGGCCTATGTAATTCTCACCTACA  
TCCTCTGCTCAACATGCTCATCGCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGG  
AGAGCAAGAACATCTGGAAGCTGCAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCT  
TCCTTAAGTGCATGAGGAAGGCCTTCCGCTCAGGCAAGCTGTGTCAGGTGGGTACACAC  
CTGATGGCAAGGACGACTACCGGTGGTGCTTCAGGGTGGACGAGGTGAAGTGGACCACCT  
15 GGAACACCAACGTGGGCATCATCAACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCA  
CCCTGAGCTTCTCCCTGCGGTCAAGCAGAGTTTCAGGCAGACACTGGAAGAAGTTTGCC  
TGGTCCCCCTTTTAAGAGAGGCAAGTGCTCGAGATAGGCAGTCTGCTCAGCCCCGAGGAAG  
TTTATCTGCGACAGTTTTCAGGGTCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTC  
20 CTGCCGCTTCCGGGGAGAAGTGAGGACGTCACGCAGACAGCACTGTCAACACTGGGCCTT  
AGGAGACCCCGTTGCCACGGGGGGCTGCTGAGGGAACACCAGTGCTCTGTCAGCAGCCTG  
GCCGTGGTCTGTGCCTGCCCAGCATGTTCCCAAATCTGTGCTGGACAAGCTGTGGGAAGCG  
TTCTTGAAGCATGGGGAGTGATGTACATCCAACCGTCACTGTCCCCAAGTGAATCTCT  
25 AACAGACTTTCAGGTTTTTACTCACTTTACTAAACAGTKTGATGGTCAGTCTCTACTGG  
GACATGTTAGGCCCTTGTTTTCTTTGATTTTATTCTTTTTTTTGAGACAGAATTTCACTC  
TTCTCACCAGGCTGGAATGCAGTGGCACAATTTTGGCTCCCTGCAACCTCCGCCTCCTG  
GATTCAGCAATTCTCTGCCTCGGCTTCCCAAGTAGCTGGGATTACAGGCACGTGCCAC  
30 CATGTCTGGCTAATTTTTTGTATTTTTTAATAGATATGGGGTTTCGCCATGTTGGCCAG  
GCTGGTCTCGAACTCCTGACCTCAGGTGATCCGCCACCTCGGCCTCCCAAAGTGCTGGG  
ATTACAGGTGTGAGCCTCCACACCTGGCTGTTTTCTTTGATTTTATTCTTTTTTTTTTT  
TCTGTGAGACAGAGTTTCACTCTTGTGCCCCAGGCTGGAGTGCAGTGGTGTGATCTTGGC  
35 TCACTGCAACTTCTGCCTCCCGGGTTCAAGCGATTCTTCTGCTTCAGTCTCCCAAGTAGC  
TTGGATTACAGGTGAGCACTACCACGCCCGGCTAATTTTTTGTATTTTAATARAGACGGG  
GTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCTTGACCTCAGGTGATCTGCCCGCCTT  
GGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCGCTGCGCTCGGCCTTCTTTGATTTT  
ATATTATTAGGAGCAAAAGTAAATGAAGCCAGGAAAACACCTTTGGGAACAACTCTTC  
40 CTTTGATGGAAAATGCAGAGGCCCTTCTCTCTGTGCGGTGCTTGCTCCTCTTACCTGCC  
CGGGTGGTTTGGGGGTGTTGGTGTTCCTCCCTGGAGAAGATGGGGGAGGCTGTCCCACT  
CCCAGCTCTGGCAGAATCAAGCTGTTGCAGCAGTGCCTTCTTCATCCTTCCTTACGATCA  
ATCACAGTCTCCAGAAGATCAGCTCAATTGCTGTGCAGGTAAAACTACAGAACCACATC  
45 CCAAAGGTACCTGGTAAGAATGTTTGAAAGATCTTCCATTTCTAGGAACCCAGTCTCTGC  
TTCTCCGCAATGGCACATGCTTCCACTCCATCCATACTGGCATCCTCAAATAAACAGATA  
TGTATACAATAAAAAAAAAAAAAAAAAAARRGCGCGCTGAATTCTAGACCTGCCCGG  
GCG

## SEQ ID NO:2

MKKWSSTDLGAAADPLQKDTCPDPLDGPNSRPPPAKPQLSTAKSRTLFGKGDSEAF

VDCPHEEGELDSCTITVSPVITIQRPDGPARGLLSQDSVAASTEKTLRLYDRRSIFE  
 AVAQNNCQDLESLLLFLQSKKHLTDNEFKDPETGKTCLLKAMNLHDGQNTTIPLLLEI  
 5 ARQTDLSKELVNASYTDSYKQQTALHIAIERRMALVTLLEVENGADVQAAAHGDFFKKT  
 KGRPGFYFGEPLSLAACTNQLGIVKFLQNSWQTADISARDSVGNTVLHALVEVADNTA  
 DNTKFVTSMYNEIILGAKLHPTLKLEELTNKGMTPLALAAGTGKIGVLAYILQREIQE  
 PECRHLRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHMLLVEPLN  
 10 RLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYRVPDGLPPFKMEKTGDYFRVTGEIL  
 SVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSLKEYVAS  
 MVFSLALGWTNMLYTRGFQOMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIE  
 DGKNDLSPSESTSHRWGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF  
 15 IILLLAYVILTYILLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKA  
 FRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTWNTNVGIINEDPGNCEGVKRTLSFSLRS  
 SRVSGRHWKINFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDA EVFKSPAASGEK

## SEQ ID NO:3

CAGCGTCGGGTGCAGTTTGGCCGGAGGTTGCAGTGAGCAGAGATTGCCCCATTGCACTCT  
 AGTCTGGGCGACAGGGTGAGACACACACACACAGACACACACACACACACACACAC  
 25 ACACAAGCCTAAACATTCRAGGCCAGGATGCTTGACAGATGTTGATTCAAAAAATGACA  
 AAAAGCACAAAATCCAAAATCTCGTATAAGCTCAGTGGCTGTGGCAGCGAGGTTGAAGAG  
 CAAAGGCAGGCCGGGCACCTGGCTGATGATGTGTGGACCCGTTGCACAGCAGGGCCCCGC  
 AGTGGCGTGTGGGTGTGGGTGTGGGTGGGCCAGTYTCTGCCGCTCACCTATTCCAGGGA  
 CACAGTCTGCTTGGCTCTTCTGGACTGAGCCATCCTCATCACCGAGATCCTCCCTGAATT  
 30 CAGCCCACGACAGCCACCCCGGCCGTTTCTCTGTCTGTGTGGGGAGGGAGGCAGCGCG  
 GTGGTTATCAACCTCACCTGCAGAGGAGGCACCTGAGGCCACAGACGAGGAGGGATGG  
 GTCTAACCACAGAACACAGATGGCTCTGAGCCGGGGGCTGTCCACCCTCCCAGGCCGAC  
 GTCAGTGCCCGCAGGACTGCCTGGGCCCTGCTAGGCCTGCTCACCTCTGAGGCCTCTGGG  
 35 GTGAGAGGTTCACTCTGGAAACACTTCAGTTCTAGGGGGCTGGGGGCAGCAGCAAGTTG  
 GAGTTTTGGGGTACCTTGCTTCACAGGGCCCTTGGCAAGGAGGGCAGGTGGGGTCTAAGG  
 ACAAGCAGTCCTTACTTTGGGAGTCAACCCCGCGTGGTGGCTGCTGCAGGTTGCACACT  
 GGGCCACAGAGGATCCAGCAAGGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTG  
 40 CGGACCCACTCCAAAAGGACACCTGCCCAGACCCCTGGATGGAGACCCTAACTCCAGGC  
 CACCTCCAGCCAAGCCCCAGCTCTCCACGGCCAAGAGCCGACCCGGCTCTTTGGGAAGG  
 GTGACTCGGAGGAGGCTTTCCCGGTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCT  
 GCCCGACCATCACAGTCAGCCCTGTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCG  
 GTGCCAGGCTGCTGTCCAGGACTCTGTCCCGCCAGCACCGAGAAGACCTCAGGCTCT  
 45 ATGATCGCAGGAGTATCTTTGAAGCCGTTGCTCAGAATAACTGCCAGGATCTGGAGAGCC  
 TGCTGCTCTTCCTGCAGAAGAGCAAGAAGCACYTCACAGACAACGAGTTCAAAGACCTG  
 AGACAGGGAAGACCTGTCTGCTGAAAGCCATGCTCAACCTGCACGACGGACAGAACACCA  
 CCATCCCCCTGCTCCTGGAGATCGCGCGGCAACCGACAGCCTGAAGGAGCTTGTCACG  
 50 CCRGCTACACGGACAGSTACTACAAGGCCAGACAGCACTGCACATCGCCATCGAGAGAC  
 GCAACATGGCCCTGGTGACCCTCCTGGTGGAGAACGGAGCAGACGTCCAGGCTGCGGCCC  
 ATGGGGACTTCTTTAAGAAAACCAAGGGCGGCCTGGATTCTACTTCGGTGAACTGCCCC



TGTCCCTGGCCGCGTGCACCAACCAGCTGGGCATCGTGAAGTTCTGCTGCAGAACTCCT  
 GGCAGACGGCCGACATCAGCGCCAGGACTCGGTGGGCAACACGGTGCTGCACGCCCTGG  
 TGGAGGTGGCCGACAACACGGCCGACAACACGAAGTTTGTGACGAGCATGTACAATGAGA  
 5 TTCTGATCCTGGGGGCCAACTGCACCCGACGCTGAAGCTGGAGGAGCTCACCAACAAGA  
 AGGGAATGACGCCGCTGGCTCTGGCAGCTGGGACCGGAAGATCGGGGTCTTGGCCTATA  
 TTCTCCAGCGGGAGATCCAGGAGCCCCAGTGCAGGCACCTGTCCAGGAAGTTCACCGAGT  
 GGGCCTACGGGCCCCGTGCACTCCTCGCTGTACGACCTGTCTGCATCGACACCTGCGAGA  
 10 AGAACTCGGTGCTGGAGGTGATCGCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACA  
 TGCTCTTGGTGGAGCCGCTGAACCGACTCCTGCAGGACAAGTGGGACAGATTCTGCAAGC  
 GCATCTTCTACTTCAACTTCCTGGTCTACTGCCTGTACATGATCATCTTACCATGGCTG  
 CCTACTACAGGCCCCGTGGATGGCTTGCCTCCCTTTAAGATGGAAAAAACTGGAGACTATT  
 15 TCCGAGTTACTGGAGAGATCCTGTCTGTGTTAGGAGGAGTCTACTTCTTTTCCGAGGGA  
 TTCAGTATTTCTTGCAGAGGCGGCCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTG  
 AGATGCTTTTCTTCTGCAGTCACTGTTTCTGCTGGCCACCGTGGTGCTGTACTTCAGCC  
 ACCTCAAGGAGTATGTGGCTTCCATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGC  
 20 TCTACTACACCCGCGGTTTCCAGCAGATGGGCATCTATGCCGTCATGATAGAGAAGATGA  
 TCCTGAGAGACCTGTGCCGTTTCTATGTTTGTCTACATCGTCTTCTTGTTCGGGTTTCCA  
 CAGCGGTGGTGACGCTGATTGAAGACGGGAAGAATGACTCCCTGCCGCTCTGAGTCCACGT  
 CGCACAGGTGGCGGGGGCTGCCTGCAGGCCCCCCGATAGCTCCTACAACAGCCTGTACT  
 25 CCACCTGCCTGGAGCTGTTCAAGTTTACCATCGGCATGGGCGACCTGGAGTTCACTGAGA  
 ACTATGACTTCAAGGCTGTCTTCATCATCCTGTGCTGGCCTATGTAATTCTCACCTACA  
 TCCTCCTGCTCAACATGCTCATCGCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGG  
 AGAGCAAGAACATCTGGAAGCTGCAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCT  
 30 TCCTTAAGTGCATGAGGAAGGCCTTCCGCTCAGGCAAGCTGCTGCAGGTGGGGTACACAC  
 CTGATGGCAAGGACGACTACCGGTGGTGCTTCAGGGTGGACGAGGTGAACTGGACCACCT  
 GGAACACCAACGTGGGCATCATCAACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCA  
 CCCTGAGCTTCTCCCTGCGGTCAAGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCC  
 35 TGGTCCCCCTTTTAAAGAGAGGCAAGTGCTCGAGATAGGCAGTCTGCTCAGCCCGAGGAAG  
 TTTATCTGCGACAGTTTTTCAGGGTCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTC  
 CTGCCGCTTCCGGGGAGAAGTGAGGACGTCACGCAGACAGCACTGTCAACACTGGGCCTT  
 AGGAGACCCCGTTGCCACGGGGGGCTGCTGAGGGAACACCAGTGCTCTGTCTCAGCAGCCTG  
 40 GCCTGGTCTGTGCCTGCCCAGCATGTTCCCAAATCTGTGCTGGACAAGCTGTGGGAAGCG  
 TTCTTGGAAGCATGGGGAGTGATGTACATCCAACCGTCACTGTCCCCAAGTGAATCTCCT  
 AACAGACTTTCAGGTTTTTACTCACTTTACTAAACAGTKTGATGGTCAGTCTCTACTGG  
 GACATGTTAGGCCCTTGTTTTCTTTGATTTTATTCTTTTTTTTGGAGACAGAATTTCACTC  
 45 TTCTCACCCAGGCTGGAATGCAGTGGCACAATTTTGGCTCCCTGCAACCTCCGCCTCCTG  
 GATTCCAGCAATTCTCCTGCCTCGGCTTCCCAAGTAGCTGGGATTACAGGCACGTGCCAC  
 CATGTCTGGCTAATTTTTTGTATTTTTTAAATAGATATGGGGTTTCGCCATGTTGGCCAG  
 GCTGGTCTCGAACTCCTGACCTCAGGTGATCCGCCACCTCGGCCTCCCAAAGTGCTGGG  
 50 ATTACAGGTGTGAGCCTCCACACCTGGCTGTTTTCTTTGATTTTATTCTTTTTTTTTT  
 TCTGTGAGACAGAGTTTCACTCTTGTGCCCAGGCTGGAGTGCAAGTGGTGTGATCTTGGC  
 TCACTGCAACTTCTGCCTCCCGGGTTCAAGCGATTCTTCTGCTTCAGTCTCCCAAGTAGC  
 TTGGATTACAGGTGAGCACTACCACGCCCCGCTAATTTTTGTATTTTAAATARAGACGGG

5 GTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCTTGACCTCAGGTGATCTGCCCCGCTT  
GGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCGCTGCGCTCGGCCTTCTTTGATTTT  
ATATTATTAGGAGCAAAAGTAAATGAAGCCCAGGAAACACCTTTGGGAACAAACTCTTC  
CTTTGATGGAAAATGCAGAGGCCCTTCCTCTCTGTGCCGTGCTTGCTCCTCTTACCTGCC  
CGGGTGGTTTGGGGGTGTTGGTGTTCCTCCCTGGAGAAGATGGGGGAGGCTGTCCCACT  
CCCAGCTCTGGCAGAATCAAGCTGTTGCAGCAGTGCTTCTTCATCCTTCCTTACGATCA  
10 ATCACAGTCTCCAGAAGATCAGCTCAATTGCTGTGCAGGTAAAACTACAGAACCACATC  
CCAAAGGTACCTGGTAAGAATGTTTGAAGATCTTCCATTTCTAGGAACCCAGTCCTGC  
TTCTCCGCAATGGCACATGCTTCCACTCCATCCATACTGGCATCCTCAAATAAACAGATA  
TGTATACAATAAAAAAAAAAAAAAAAAAAAAARRGCGCGCTGAATTCTAGACCTGCCCCG  
15 GCG

## SEQ ID NO:4

20 MKKWSSTDLGAAADPLQKDTCPDPLDGDPSRPPPAKPQLSTAKSRTLFGKGDSEEAFF  
VDCPHEEGELDSCTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLLRLYDRRSIFE  
AVAQNNCQDLESLLLFLQSKKHXTDNEFKDPETGKTCLLKAMNLHDGQNTTIPLLLEI  
ARQTDLSKELVNAXYTDXYKQGTALHIAIERRNMAVLTLLVENGADVQAAAHGDFFKKT  
KGRPGFYFGEPLSLAACTNQLGIVKFLQNSWQTADISARDSVGNTVLHALVEVADNTA  
25 DNTKFVTSMYNEILILGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQE  
PECRHLRKRKTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLN  
RLQDKWDRFVKRIFYFNFLVCLYMIIFTMAAYRPPVDGLPPFKMEKTGDYFRVTGEIL  
SVLGGVYFFFRGIQYFLQRRPSMKTLEFVDSYSEMLFFLQSLFMLATVVLYFSLKEYVAS  
30 MVFSLALGWTNMLYYTRGFOQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIE  
DGKNDSLPSESTSHRWGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF  
IILLLAYVILTYIILLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSLKCMRKA  
FRSGKLLQVGYTPDGKDDYRWCFRVDENVWTTWNTNVIINEDPGNCEGVKRTLSFSLRS  
35 SRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAIEVFKSPAASGEK

## SEQ ID NO:5

40 GAGCTTCTCCCTGCGGTCAAGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCCCTGGT  
CCCCCTTTTAAGAGAGGCAAGTNCTCGANATAGGCAGTCTGCTCAGCCGAGGAAGTTTA  
TCTGCGACAGTTTTCAGGGTCTCTAAAGCCAGAGGACGCTGAGGTCTTCAAGAGTCCTGC  
CGCTTCCGGGGAGAAGTGAGGACGTACGCAGACAGCACTGTCAACACTGGGCCTTAGGA  
GACCCCGTTGCCACGGGGGGCTGCTGAGGGAACACCAGTGCTTTTTCAGCAGCCTTGCTT  
45 GGGTCTTTGCCCTGCCAGCATGTTCCCAAATCTGTGCTGGACAAGCTGTGGGGAAGCGTT  
CTTGGGAAGCATGGGGGAGTGATGTTACATCCAACCGTCACTGTCCCAAGTTGAATCTT  
CCTTAACAGATT

## SEQ ID NO:6

50 SFSLRSSRVSGRHWKNFALVPLLREASRXRQSAQPEEVYLRQFSGSLKPEDAIEVFKSPA  
ASGEK

## SEQ ID NO:7, PVP-1 (polymorphic variant of VANILREP1, A2625G)

CAGCGTCGGGTGCAGTTTGGCCGGAGGTTGCAGTGAGCAGAGATTGCCCCATTGCACTCT  
 AGTCTGGGCGACAGGGTGAGACACACACACACAGACACACACACACACACACACAC  
 ACACAAGCCTAAACATTTCRAGGCCAGGATGCTTGACAGATGTTGATTCATAAAATGACA  
 AAAAGCACAAAATCCAAAATCTCGTATAAGCTCAGTGGCTGTGGCAGCGAGGTTGAAGAG  
 CAAAGGCAGGCCGGGCACCTGGCTGATGATGTGTGGACCCGTTGCACAGCAGGGCCCCGC  
 AGTGCGGTGTGGGTGTGGGTGTGGGTGGGCCAGTYTCTGCCGCTCACCCCTATTCCAGGGA  
 CACAGTCTGCTTGGCTCTTCTGGACTGAGCCATCCTCATACCGAGATCCTCCCTGAATT  
 CAGCCACGACAGCCACCCCGCCGTTTTCCTTGTCTGTGTGGGGAGGGAGGCAGCGCG  
 GTGGTTATCAACCTCACCTGCAGAGGAGGCACCTGAGGCCAGAGACGAGGAGGGATGG  
 GTCTAACCCAGAACCACAGATGGCTCTGAGCCGGGGGCTGTCCACCCTCCCAGGCCGAC  
 GTCAGTGCCCGCAGGACTGCCTGGGCCCTGCTAGGCCTGCTACCTCTGAGGCCTCTGGG  
 GTGAGAGGTTTCAGTCTTGAAACACTTCAGTTCTAGGGGGCTGGGGCAGCAGCAAGTTG  
 GAGTTTTGGGGTACCTGCTTCACAGGGCCCTTGGCAAGGAGGGCAGGTGGGGTCTAAGG  
 ACAAGCAGTCCTTACTTTGGGAGTCAACCCCGCGTGGTGGCTGCTGCAGGTTGCACACT  
 GGGCCACAGAGGATCCAGCAAGGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTG  
 CGGACCCACTCCAAAAGGACACCTGCCAGACCCCTGGATGGAGACCCTAACTCCAGGC  
 CACCTCCAGCCAAGCCCCAGCTCTCCACGGCCAAGAGCCGACCCGGCTCTTTGGGAAGG  
 GTGACTCGGAGGAGGCTTTCCCGGTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCT  
 GCCCGACCATCACAGTCAGCCCTGTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCG  
 GTGCCAGGCTGCTGTCCAGGACTCTGTCCGCCCAGCACCAGAGAAGACCCTCAGGCTCT  
 ATGATCGCAGGAGTATCTTTGAAGCCGTGCTCAGAATAACTGCCAGGATCTGGAGAGCC  
 TGCTGCTCTTCCCTGCAGAAGAGCAAGAAGCACCTCACAGACAACGAGTTCAAAGACCCTG  
 AGACAGGGAAGACCTGTCTGCTGAAAGCCATGCTCAACCTGCACGACGGACAGAACACCA  
 CCATCCCCCTGCTCCTGGAGATCGCGCGGCAAACGGACAGCCTGAAGGAGCTTGTCACCG  
 CCAGCTACACGGACAGCTACTACAAGGGCCAGACAGCACTGCACATCGCCATCGAGAGAC  
 GCAACATGGCCCTGGTGACCCTCCTGGTGGAGAACGGAGCAGACGTCCAGGCTGCGGCCC  
 ATGGGGACTTCTTTAAGAAAACCAAAGGGCGGCTGGATTCTACTTCGGTGAAGTCCCCC  
 TGTCCCTGGCCGCTGCACCAACCAGCTGGGCATCGTGAAGTTCCTGCTGCAGAACTCCT  
 GGCAGACGGCCGACATCAGCGCCAGGGACTCGGTGGGCAACACGGTGCTGCACGCCCTGG  
 TGGAGGTGGCCGACAACACGGCCGACAACACGAAGTTTGTGACGAGCATGTACAATGAGA  
 TTCTGATCCTGGGGGCCAAACTGCACCCGACGCTGAAGCTGGAGGAGCTCACCAACAAGA  
 AGGGAATGACGCCGCTGGCTCTGGCAGCTGGGACCGGAAGATCGGGGTCTTGGCCTATA  
 TTCTCCAGCGGGAGATCCAGGAGCCCGAGTGCAGGCACCTGTCCAGGAAGTTCACCGAGT  
 GGGCCTACGGGCCCCGTGCACTCCTCGCTGTACGACCTGTCTGTCATCGACACCTGCGAGA  
 AGAACTCGGTGCTGGAGGTGATCGCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACA  
 TGCTCTTGGTGGAGCCGCTGAACCGACTCCTGCAGGACAAGTGGGACAGATTCTGCAAGC  
 GCATCTTCTACTTCAACTTCTGGTCTACTGCCTGTACATGATCATCTTCACCATGGCTG  
 CCTACTACAGGCCCCGTGGATGGCTTGCCCTCCCTTTAAGATGGAAAAAAGTGGAGACTATT  
 TCCGAGTTACTGGAGAGATCCTGTCTGTGTTAGGAGGAGTCTACTTCTTTTCCGAGGGA  
 TTCAGTATTTCTGTCAGAGGCGGCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTG  
 AGATGCTTTTCTTCTGCACTCACTGTTTCATGCTGGCCACCGTGGTGCTGTACTTCAGCC

ACCTCAAGGAGTATGTGGCTTCCATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGC  
TCTACTACACCCGCGGTTTTCCAGCAGATGGGCATCTATGCCGTCATGATAGAGAAGATGA  
5 TCCTGAGAGACCTGTGCCGTTTCATGTTTGTCTACGTCGTCTTCTTGTTCGGGTTTTCCA  
CAGCGGTGGTGACGCTGATTGAAGACGGGAAGAATGACTCCCTGCCGTCTGAGTCCACGT  
CGCACAGGTGGCGGGGGCCTGCCTGCAGGCCCCCGATAGCTCCTACAACAGCCTGTACT  
CCACCTGCCTGGAGCTGTTCAAGTTCACCATCGGCATGGGCGACCTGGAGTTCACTGAGA  
10 ACTATGACTTCAAGGCTGTCTTCATCATCCTGCTGCTGGCCTATGTAATTCTCACCTACA  
TCCTCCTGCTCAACATGCTCATCGCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGG  
AGAGCAAGAACATCTGGAAGCTGCAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCT  
TCCTTAAGTGATGAGGAAGGCCTTCCGCTCAGGCAAGCTGCTGCAGGTGGGGTACACAC  
15 CTGATGGCAAGGACGACTACCGGTGGTGTCTCAGGGTGGACGAGGTGAACTGGACCACCT  
GGAACACCAACGTGGGCATCATCAACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCA  
CCCTGAGCTTCTCCCTGCGGTCAAGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCCC  
TGGTCCCCCTTTTAAGAGAGGCAAGTGCTCGAGATAGGCAGTCTGCTCAGCCCGAGGAAG  
20 TTTATCTGCGACAGTTTTCAGGGTCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTC  
CTGCCGCTTCCGGGGAGAAGTGAGGACGTACGCAGACAGCACTGTCAACACTGGGCCTT  
AGGAGACCCCGTTGCCACGGGGGGCTGCTGAGGGAACACCAGTGCTCTGTCAGCAGCCTG  
25 GCCTGGTCTGTGCCTGCCCA

**SEQ ID NO:8, (PVP-1 protein, I585V)**

MKKWSSTD LGAAADPLQKDTCPDPLDGDPSNRPPPAKPQLSTAKSRTLFGKGDSEEAFF  
30 VDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFE  
AVAQNNCQDLESLLLFLQSKKHLTDNEFKDPETGKTCLLKAMNLNHDGQNTTIPLLLEI  
ARQDLSLKVNASYTDSSYKGTALHIAIERRNMALVTLLVENGADVQAAAHGDDFFKKT  
KGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTA  
35 DNTKFVTSMYNEILILGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQE  
PECRHLSRKFTWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLN  
RLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYRPPVDGLPPFKMEKTGDYFRVTGEIL  
SVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLVYFSLKEYVAS  
40 MVFSLALGWTNMLYYTRGFQMGIIYAVMIEKMILRDLCRFMFVYVFLFGFSTAVVTLIE  
DGKNDSLPSESTSHRWGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF  
IILLLAYVILTYILLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKA  
45 FRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTWNTNVI INEDPGNCEGVKRTLSFSLRS  
SRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDA EVFKSPAASGEK

# EP 0 943 683 A1

## SEQUENCE LISTING

5 <110> SmithKline Beecham plc

<120> Novel Compounds

10 <130> GP30075

<160> 8

15 <170> FastSEQ for Windows Version 3.0

<210> 1

<211> 4803

20 <212> DNA

<213> Homo sapiens

25 <400> 1

cagcgtcggg	tgagtttgg	ccggaggttg	cagtgcagcag	agattgcccc	attgcactct	60
agtctggg	acagggtag	acacacacac	acagacacac	acacacacac	acacacacac	120
acacaagcct	aaacattcra	ggccaggatg	cttgacagat	gttgattcat	aaaaatgaca	180
aaaagcaca	aatccaaaat	ctcgtataag	ctcagtggtc	gtggcagcga	ggttgaagag	240
caaaggcagg	ccggggcacct	ggctgatgat	gtgtggaccc	gttgacacag	agggccccgc	300
agtgcgggtg	gggtgtgggt	gtgggtgggc	cagtytctgc	cgtccaccct	attccaggga	360
cacagtctgc	ttggtcttc	tggactgagc	catcctcatc	accgagatcc	tcctgaatt	420
cagccccaga	cagccacccc	ggccgttttc	cttgttctgt	gtggggaggg	aggcagcgcg	480
gtggttatea	acctcacctc	gcagaggagg	cacctgaggc	ccagagacga	ggagggatgg	540
gtctaacca	gaaccacaga	tggctctgag	ccgggggcct	gtccaccctc	ccaggccgac	600
gtcagtggcc	gcaggactgc	ctggggccctg	ctaggccctgc	tcacctctga	ggcctctggg	660
gtgagagggt	cagtcctgga	aacacttcag	ttctaggggg	ctgggggcag	cagcaagttg	720
gagttttggg	gtacctgtct	tcacagggcc	cttggaagg	agggcaggtg	gggtctaagg	780
acaagcagtc	cttactttgg	gagtcacccc	cggcgtggtg	gctgctgcag	gttgcaact	840
gggccacaga	ggatccagca	aggatgaaga	aatggagcag	cacagacttg	ggggcagctg	900
cggaccctact	ccaaaaggac	acctgcccag	accccttgga	tggagaccct	aactccaggc	960
cacctccagc	caagccccag	ctctccacgg	ccaagagccg	caccggctc	tttgggaagg	1020
gtgactcgga	ggaggctttc	ccggtggatt	gcccctcacga	ggaaggtag	ctggactcct	1080
gcccagccat	cacagtcagc	cctgttatca	ccatccagag	gccaggagac	ggccccaccg	1140
gtgccaggct	gctgtccag	gactctgtcg	ccgccagcac	cgagaagacc	ctcaggctct	1200
atgatcgag	gagtatcttt	gaagccgttg	ctcagaataa	ctgccaggat	ctggagagcc	1260
tgctgtctct	cctgcagaag	agcaagaagc	acctcacaga	caacgagttc	aaagaccctg	1320

55

EP 0 943 683 A1

	agacagggaa gacctgtctg ctgaaagcca tgctcaacct gcacgacgga cagaacacca	1380
	ccatccccct gctcctggag atcgcgcggc aaacggacag cctgaaggag cttgtcaacg	1440
5	ccagctacac ggacagctac tacaagggcc agacagcact gcacatcgcc atcgagagac	1500
	gcaacatggc cctggtgacc ctccctgggtg agaacggagc agacgtccag gctgcggccc	1560
	atggggactt ctttaagaaa accaaagggc ggccctggatt ctacttcggt gaactgcccc	1620
	tgccccggc cgcgtgcacc aaccagctgg gcacgtgaa gtccctgctg cagaactcct	1680
10	ggcagacggc cgacatcagc gccagggact cgggtgggcaa cagggtgctg cagccctgg	1740
	tggaggtggc cgacaacacg gccgacaaca cgaagtctgt gacgagcatg tacaatgaga	1800
	ttctgatact gggggccaaa ctgcaccgca cgctgaagct ggaggagctc accaacaaga	1860
	agggaaatgac gccgctggct ctggcagctg ggaccgggaa gatcggggtc ttggcctata	1920
15	ttctccagcg ggagatccag gagcccgagt gcaggcacct gtccaggaag ttcaccgagt	1980
	gggcctacgg gcccgctgac tccctgctgt acgacctgtc ctgcatcgac acctgcgaga	2040
	agaactcggg gctggagggtg atcgccctaca gcagcagcga gacccctaata cgccacgaca	2100
	tgctcttggg ggagccgctg aaccgactcc tgcaggacaa gtgggacaga ttcgtcaagc	2160
20	gcactctcta cttcaacttc ctgggtctact gcctgtacat gatcatcttc accatggctg	2220
	cctactacag gcccgctggat ggcttgcctc cctttaagat ggaaaaaact ggagactatt	2280
	tccgagttac tggagagatc ctgtctgtgt taggaggagt ctacttcttt tcccgaggga	2340
	ttcagtattt cctgcagagg cggccgtcga tgaagacct gtttgtggac agctacagtg	2400
25	agatgctttt ctttctgcag tcaactgttc tgctggccac cgtggtgctg tacttcagcc	2460
	acctcaagga gtatgtggct tccatggtat tctccctggc cttgggctgg accaactatg	2520
	tctactacac ccgcggtttc cagcagatgg gcactctatg cgtcatgata gagaagatga	2580
	tccctgagaga cctgtgccgt ttcattgttg tctacatcgt cttcttgttc ggggtttcca	2640
30	cagcgggtgg gacgctgatt gaagacggga agaatactc cctgccgtct gagtccacgt	2700
	cgcacaggtg scggggggcct gcctgcaggc cccccgatag ctccctacaac agcctgtact	2760
	ccacctgcct ggagctgttc aagttcacca tcggcatggg cgacctggag ttcactgaga	2820
	actatgactt caaggctgtc ttcacatccc tgctgctggc ctatgtaatt ctcacctaca	2880
35	tccctcctgct caacatgctc atcgccctca tgggtgagac tgtcaacaag atcgcacagg	2940
	agagcaagaa catctggaag ctgcagagag ccatacccat cctggacacg gagaagagct	3000
	tcccttaagt catgaggaag gccttccgct caggcaagct gctgcagggt ggggtacacac	3060
	ctgatggcaa ggacgactac cgggtggtgt tcagggtgga cgagggtgaac tggaccacct	3120
40	ggaacaccaa cgtgggcacg atcaacgaag acccgggcaa ctgtgagggc gtcaagcgca	3180
	ccctgagctt ctccctgcgg tcaagcagag tttcaggcag aactggaag aactttgcc	3240
	tgggtccccct ttttaagagag gcaagtgtc gagataggca gtctgctcag cccgaggaag	3300
	tttatctgag acagttttca ggggtctctga agccagagga cgctgaggtc ttcaagagtc	3360
45	ctgccgcttc cggggagaag tgaggacgtc acgcagacag cactgtcaac actgggcctt	3420
	aggagacccc gttgccacgg ggggctgtc agggaaacac agtgctctgt cagcagcctg	3480
	gcctgggtctg tgccctgccc gcatgttccc aaatctgtgc tggacaagct gtggggaagc	3540
	ttcttggaag catggggagt gatgtacac caaccgtcac tgtccccaag tgaatctcct	3600
50	aacagacttt cagggttttta ctactttac taaacagtkt ggatggtcag tctctactgg	3660
	gacatgttag gcccttgttt cttttgatct tattcttttt tttagacag aatttctctc	3720
	ttctcaccga ggcgggaatg cagtggcaca attttggtc cctgcaacct ccgcctcctg	3780
	gattccagca attctcctgc ctgggcttcc caagtagctg ggattacagg cacgtgccac	3840

55

EP 0 943 683 A1

catgtctggc taattttttg tattttttta atagatatgg gggttcgcca tgttgccag 3900  
 gctgggtctcg aactcctgac ctcaggatgat cgcgccacct cggcctccca aagtgtctggg 3960  
 5 attacaggtg tgagcctcca cacctggctg tttcttttga ttttattctt tttttttttt 4020  
 tctgtgagac agagtttcac tcttggtgcc caggctggag tgcagtgggtg tgatcttggc 4080  
 tcaactgcaac tctgcctcc cgggttcaag cgattctctt gcttcagtct cccaagtagc 4140  
 ttggattaca ggtgagcact accacgcccg gctaattttt gtatttttaa taragacggg 4200  
 10 gtttcaccat gttggccagg ctggtctcga actcttgacc tcaggatgac tgcctgcctt 4260  
 ggcctcccaa agtgtctggga ttacaggtgt gagccgctgc gctcggcctt ctttgatatt 4320  
 atattattag gagcaaaagt aaatgaagcc caggaaaaca cctttgggaa caaactcttc 4380  
 ctttgatgga aaatgcagag gcccttctc tctgtgcctg gcttgcctct cttacctgcc 4440  
 15 cgggtgggtt ggggtgtgtg gtgttctct cctggagaag atgggggagg ctgtccact 4500  
 cccagctctg gcagaatcaa gctgttgag cagtgccttc ttcactcttc cttacgatca 4560  
 atcacagtct ccagaagatc agctcaattg ctgtgcaggt taaaactaca gaaccacatc 4620  
 ccaaaggtag ctggttaagaa tgtttgaaag atcttccatt tctaggaacc ccagtctgc 4680  
 ttctccgcaa tggcacatgc ttcactcca tccatactgg catcctcaaa taaacagata 4740  
 20 tgtatacaat aaaaaaaaaa aaaaaaaaaa rrgcgccgc tgaattctag acctgcccg 4800  
 gcg 4803

<210> 2  
 25 <211> 839  
 <212> PRT  
 <213> Homo sapiens

30 <400> 2  
 Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu  
 1 5 10 15  
 Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg  
 35 20 25 30  
 Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg  
 35 40 45  
 Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro  
 40 50 55 60  
 His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro  
 65 70 75 80  
 Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu  
 45 85 90 95  
 Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu  
 100 105 110  
 Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln  
 50 115 120 125  
 Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu  
 130 135 140

55

EP 0 943 683 A1

Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu  
 145 150 155 160  
 5 Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu  
 165 170 175  
 Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn  
 180 185 190  
 10 Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile  
 195 200 205  
 Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn  
 210 215 220  
 15 Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr  
 225 230 235 240  
 Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala  
 245 250 255  
 20 Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser  
 260 265 270  
 Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val  
 275 280 285  
 25 Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys  
 290 295 300  
 Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu  
 305 310 315 320  
 30 His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Thr  
 325 330 335  
 Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr  
 340 345 350  
 35 Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg  
 355 360 365  
 Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp  
 370 375 380  
 40 Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile  
 385 390 395 400  
 Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val  
 405 410 415  
 45 Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys  
 420 425 430  
 Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile  
 435 440 445  
 50 Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe  
 450 455 460  
 Lys Met Glu Lys Thr Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu  
 465 470 475 480

55



EP 0 943 683 A1

	Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe		
	485	490	495
5	Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser		
	500	505	510
	Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val		
	515	520	525
10	Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser		
	530	535	540
	Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln		
	545	550	555
	Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp		
15	565	570	575
	Leu Cys Arg Phe Met Phe Val Tyr Ile Val Phe Leu Phe Gly Phe Ser		
	580	585	590
20	Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro		
	595	600	605
	Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro		
	610	615	620
25	Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys		
	625	630	635
	Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe		
	645	650	655
30	Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr		
	660	665	670
	Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn		
	675	680	685
35	Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile		
	690	695	700
	Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala		
	705	710	715
	Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys		
40	725	730	735
	Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr		
	740	745	750
45	Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu		
	755	760	765
	Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser		
	770	775	780
50	Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala		
	785	790	795
	Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg		
	805	810	815

# EP 0 943 683 A1

Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser

820

825

830

Pro Ala Ala Ser Gly Glu Lys

835

<210> 3

<211> 4803

<212> DNA

<213> Homo sapiens

<400> 3

cagcgtcggg	tgcaagtttg	ccggagggtg	cagtgaagcag	agattgcccc	attgcactct	60
agtctgggag	acagggtgag	acacacacac	acagacacac	acacacacac	acacacacac	120
acacaagcct	aaacattcra	ggccaggatg	cttgacagat	gttgattcat	aaaaatgaca	180
aaaagcacia	aatccaaaat	ctcgtataag	ctcagtggct	gtggcagcga	ggttgaagag	240
caaaggcagg	ccggggcacct	ggctgatgat	gtgtggaccc	gttgacacag	agggccccgc	300
agtgcgggtg	gggtgtgggt	gtgggtgggc	cagtytctgc	cgctcaccct	attccaggga	360
cacagtctgc	ttggctcttc	tggactgagc	catcctcctc	accgagatcc	tccctgaatt	420
cagccccaga	cagccacccc	ggccggtttc	cttgttctgt	gtggggaggg	aggcagcgcg	480
gtggttatca	acctcaccct	gcagaggagg	cacctgaggc	ccagagacga	ggagggatgg	540
gtctaacca	gaaccacaga	tggctctgag	ccgggggctc	gtccaccctc	ccaggccgac	600
gtcagtggcc	gcaggactgc	ctgggcccct	ctaggccctg	tcacctctga	ggcctctggg	660
gtgagagggt	cagtcctgga	aacacttcag	ttctaggggg	ctggggggcag	cagcaagttg	720
gagttttggg	gtaccctgct	tcacaggggc	cttggaagg	agggcagggt	gggtctaagg	780
acaagcagtc	cttacttttg	gagtcacccc	cggcgtgggt	gctgctgcag	gttgcacact	840
gggccacaga	ggatccagca	aggatgaaga	aatggagcag	cacagacttg	ggggcagctg	900
cggaccactc	ccaaaaggac	acctgcccag	accccttgga	tggagaccct	aactccaggc	960
cacctccagc	caagccccag	ctctccacgg	ccaagagccg	caccgggctc	tttgggaagg	1020
gtgactcggg	ggaggctttc	ccgggtggatt	gccctcacga	ggaagggtgag	ctggactcct	1080
gcccgaccat	cacagtcagc	cctgttatca	ccatccagag	gccaggagac	ggccccaccg	1140
gtgccaggct	gctgtcccag	gactctgtcg	ccgccagcac	cgagaagacc	ctcaggctct	1200
atgatcgtag	gagtatcttt	gaagccgttg	ctcagaataa	ctgccaggat	ctggagagcc	1260
tgctgctctt	cctgcagaag	agcaagaagc	acytcacaga	caacgagttc	aaagaccctg	1320
agacagggaa	gacctgtctg	ctgaaagcca	tgctcaacct	gcacgacgga	cagaacacca	1380
ccatccccct	gctcctggag	atcgcgcggc	aaacggacag	cctgaaggag	cttgtcaacg	1440
ccrgctacac	ggacagstac	tacaagggcc	agacagcact	gcacatcgcc	atcgagagac	1500
gcaacatggc	cctgggtgacc	ctcctgggtg	agaacggagc	agacgtccag	gctgcggccc	1560
atggggactt	ctttaagaaa	accaaagggc	ggcctggatt	ctacttcggg	gaactgcccc	1620
tgccctggc	cgcgtgcacc	aaccagcttg	gcacgtgaa	gttcctgctg	cagaactcct	1680
ggcagacggc	cgacatcagc	gccagggact	cgggtgggcaa	cacggtgctg	cacgccttgg	1740
tggagggtgg	cgacaacacg	gccgacaaca	cgaagtttgt	gacgagcatg	tacaatgaga	1800
ttctgatcct	ggggggccaaa	ctgcacccga	cgtgaagct	ggaggagctc	accaacaaga	1860

EP 0 943 683 A1

	agggaaatgac gccgctggct ctggcagctg ggaccgggaa gatcgggggc ttggcctata	1920
	ttctccagcg ggagatccag gagcccgagt gcaggcacct gtccaggaag ttcaccgagt	1980
5	gggcctacgg gcccggtgcac tectcgctgt acgacctgtc ctgcatcgac acctgcgaga	2040
	agaactcggg gctggagggtg atcgccctaca gcagcagcga gaccacctaat cgccacgaca	2100
	tgctcttggg ggagccgctg aaccgactcc tgcaggacaa gtgggacaga ttcgtcaagc	2160
	gcattcttcta cttaacttc ctggtctact gcctgtacat gatcatcttc accatggctg	2220
10	cctactacag gcccggtggat ggcttgcttc cctttaagat ggaaaaaact ggagactatt	2280
	tccgagttac tggagagatc ctgtctgtgt taggaggagt ctacttcttt tccgagggga	2340
	ttcagtattt cctgcagagg cggccgctga tgaagacct gtttggggac agctacagtg	2400
	agatgctttt cttctctgag tcactgttca tgcctggccac cgtgggtgctg tacttcagcc	2460
15	acctcaagga gtatgtggct tccatggtat tctccctggc cttgggctgg accaaccatgc	2520
	tctactacac ccgcggttcc cagcagatgg gcattctatgc cgtcatgata gagaagatga	2580
	tcctgagaga cctgtgccgt ttcattgtttg tctacatcgt cttcttcttc gggttttcca	2640
	cagcgggtggg gacgctgatt gaagacggga agaattgactc cctgccgtct gaggccacgt	2700
20	cgacacgggtg gcgggggcct gctgcagggc ccccgatag ctctacaac agcctgtact	2760
	ccacctgcct ggagctgttc aagtccacca tgcgcattggg cgacctggag ttcactgaga	2820
	actatgactt caaggctgtc ttcattcatcc tgcctgctggc ctatgtaatt ctcacctaca	2880
	tctcctgctt caacatgctc atcgccctca tgggtgagac tgtcaacaag atcgcacagg	2940
25	agagcaagaa catctggaag ctgcagagag ccatcaccat cctggacacg gagaagagct	3000
	tccttaagtg catgaggaa gcttctccgt caggcaagct gctgcagggtg gsgtacacac	3060
	ctgatggcaa ggacgactac cgggtggtgct tcagggtgga cgagggtgaac tggaccacct	3120
	ggaacaccaa cgtgggcatc atcaacgaag acccgggcaa ctgtgagggc gtcaagcgca	3180
30	ccttgagctt cctccctgcg tcaagcagag ttccaggcag acactggaag aactttgccc	3240
	tggccccctt ttaagagag gcaagtgtc gagataggca gtctgctcag cccgaggaag	3300
	tttatctgcg acagttttca gggctctctga agccagagga cgtgagggtc ttcgaaggtc	3360
	ctgcgccttc cggggagaag tgaggacgtc acgcagacag cactgtcaac actgggcctt	3420
	aggagacccc gttgccacgg ggggctgctg agggaaacacc agtgcctctgt cagcagcctg	3480
35	gcctgggtctg tgcctgcccc gcattgtccc aaatctgtgc tggacaagct gtgggaagcg	3540
	ttcttggaag catggggagt gatgtacac caaccgtcac tgtccccaag tgaatctcct	3600
	aacagacttt cagggttttta ctcactttac taaacagtkk ggatgggtcag tctctactgg	3660
	gacatgttag gcccttgctt tctttgatct tattcttttt tttagacag aatttcactc	3720
40	ttctcaccga ggctggaatg cagtggcaca attttggctc cctgcaacct ccgcctcctg	3780
	gattccagca atttctctgc ctgggcttcc caagtagctg ggattacagg cactgcccac	3840
	catgtctggc taattttttg tattttttta atagatatgg ggtttcgcca tgttggccag	3900
	gctggtctcg aactcctgac ctcagggtgat ccgcccacct cggcctccca aagtgtcggg	3960
45	attacagggtg tgagcctcca cacctggctg ttttctctga ttttattctt tttttttttt	4020
	tctgtgagac agagtttcac tcttgttgc caggctggag tgcagtgggtg tgatcttggc	4080
	tcactgcaac ttctgctcc cgggttcaag cgattcttct gcttcagtct cccaagtagc	4140
	ttggattaca ggtgagcact accacgccc gctaattttt gtatttttaa taragacggg	4200
50	gtttcaccat gttggccagg ctgggtctga actcttgacc tcagggtgac tgcctgcctt	4260
	ggcctcccaa agtgctggga ttacagggtg gagccgctgc gctcggectt ctttgatttt	4320
	atattatttag gagcaaaagt aaatgaagcc caggaaaaca cctttgggaa caaactcttc	4380

55

EP 0 943 683 A1

ctttgatgga aaatgcagag gcccttcttc tctgtgccgt gcttgctcct cttacctgcc 4440  
 cgggtgggtt gggggtgttg gtgttctctc cctggagaag atgggggagg ctgtccact 4500  
 5 cccagctctg gcagaatcaa gctgttgag cagtgccttc ttcaccttc cttacgatca 4560  
 atcacagtct ccagaagatc agctcaattg ctgtgcaggt taaaactaca gaaccacatc 4620  
 ccaaaggtag ctggtaagaa tgtttgaaag atcttccatt tctaggaacc ccagtcctgc 4680  
 ttctccgcaa tggcacatgc ttccactcca tccatactgg catcctcaaa taaacagata 4740  
 10 tgtatacaat aaaaaaaaaa aaaaaaaaaa rrgcgccgc tgaattctag acctgcccg 4800  
 gcg 4803

<210> 4

<211> 839

<212> PRT

<213> Homo sapiens

<400> 4

Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu  
 1 5 10 15  
 Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg  
 20 25 30  
 25 Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg  
 35 40 45  
 Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro  
 50 55 60  
 30 His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro  
 65 70 75 80  
 Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu  
 85 90 95  
 35 Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu  
 100 105 110  
 Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln  
 115 120 125  
 40 Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Xaa  
 130 135 140  
 Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu  
 145 150 155 160  
 45 Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu  
 165 170 175  
 Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn  
 180 185 190  
 50 Ala Xaa Tyr Thr Asp Xaa Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile  
 195 200 205  
 Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn

## EP 0 943 683 A1

210                      215                      220  
 Gly Ala Asp Val Gln Ala Ala His Gly Asp Phe Phe Lys Lys Thr  
 225                      230                      235                      240  
 Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala  
 245                      250                      255  
 Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser  
 260                      265                      270  
 Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val  
 275                      280                      285  
 Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys  
 290                      295                      300  
 Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu  
 305                      310                      315                      320  
 His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Thr  
 325                      330                      335  
 Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr  
 340                      345                      350  
 Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg  
 355                      360                      365  
 Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp  
 370                      375                      380  
 Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile  
 385                      390                      395                      400  
 Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val  
 405                      410                      415  
 Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys  
 420                      425                      430  
 Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile  
 435                      440                      445  
 Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe  
 450                      455                      460  
 Lys Met Glu Lys Thr Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu  
 465                      470                      475                      480  
 Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe  
 485                      490                      495  
 Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser  
 500                      505                      510  
 Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val  
 515                      520                      525  
 Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser  
 530                      535                      540  
 Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln

# EP 0 943 683 A1

545 550 555 560  
 Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp  
 5 565 570 575  
 Leu Cys Arg Phe Met Phe Val Tyr Ile Val Phe Leu Phe Gly Phe Ser  
 580 585 590  
 Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro  
 10 595 600 605  
 Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro  
 610 615 620  
 Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys  
 15 625 630 635 640  
 Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe  
 645 650 655  
 Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr  
 20 660 665 670  
 Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn  
 675 680 685  
 Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile  
 25 690 695 700  
 Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala  
 705 710 715 720  
 Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys  
 30 725 730 735  
 Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr  
 740 745 750  
 Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu  
 755 760 765  
 35 Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser  
 770 775 780  
 Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala  
 785 790 795 800  
 40 Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg  
 805 810 815  
 Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser  
 820 825 830  
 45 Pro Ala Ala Ser Gly Glu Lys  
 835

<210> 5

50 <211> 432

<212> DNA

<213> Homo sapiens

55

# EP 0 943 683 A1

<400> 5

5 gagcttctcc ctgcgggtcaa gcagagtttc aggcagacac tggaagaact ttgccctggt 60  
 ccccttttta agagaggcaa gtntctgana taggcagtct gctcagcccg aggaagttaa 120  
 tctgcgacag ttttcagggt ctctaaagcc agaggacgct gaggtcttca agagtcctgc 180  
 cgcttcgggg gagaagtgag gacgtcacgc agacagcact gtcaacactg ggccttagga 240  
 gaccccggtg ccacgggggg ctgctgaggg aacaccagtg ctttttcagc agccttgcc 300  
 10 gggctcttgc ctgccagca tgttcccaaa tctgtgctgg acaagctgtg gggaagcgtt 360  
 cttgggaagc atgggggagt gatgttacat ccaaccgtca ctgtcccaaa gttgaatctt 420  
 ccttaacaga tt 432

<210> 6

<211> 65

<212> PRT

<213> Homo sapiens

<400> 6

20 Ser Phe Ser Leu Arg Ser Ser Arg Val Ser Gly Arg His Trp Lys Asn  
 1 5 10 15  
 25 Phe Ala Leu Val Pro Leu Leu Arg Glu Ala Ser Xaa Arg Xaa Arg Gln  
 20 25 30  
 Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg Gln Phe Ser Gly Ser Leu  
 35 40 45  
 30 Lys Pro Glu Asp Ala Glu Val Phe Lys Ser Pro Ala Ala Ser Gly Glu  
 50 55 60  
 Lys  
 65

<210> 7

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 7

45 cagcgtcggg tgcagtttgg ccggaggttg cagtgcagcag agattgcccc attgcactct 60  
 agtctgggag acaggggtgag acacacacac acagacacac acacacacac acacacacac 120  
 acacaagcct aaacattcra ggccaggatg cttgacagat gttgattcat aaaaatgaca 180  
 aaaagcacia aatccaaaat ctctataag ctgagtggct gtggcagcga ggttgaagag 240  
 caaaggcagg ccggggcacct ggctgatgat gtgtggaccc gttgcacagc agggccccgc 300  
 50 agtgcggtgt ggggtgtgggt gtgggtgggc cagtytctgc cgctcacccct attccaggga 360  
 cacagtctgc ttggtcttct tggactgagc cactctcact accgagatcc tccctgaatt 420  
 cagccacga cagccacccc ggccgttttc cttgttctgt gtggggaggg aggcagcgcg 480

	gtggttatca acctcacctc gcagaggagg .cacctgaggc ccagagacga ggagggatcg	540
	gtctaaccaca gaaccacaga tggctctgag ccgggggacct gtccacctc ccaggccgac	600
5	gtcagtgccc gcaggactgc ctgggcccctg ctaggccctgc tcacctctga ggcctctggg	660
	gtgagagggtt cagtcctgga aacacttcag ttctaggggg ctgggggagcag cagcaagtgt	720
	gagttttggg gtacctctgt tcacaggggc cttggcaagg agggcagggtg gggctctaagg	780
	acaagcagtc cttacttttg gagtcaaccc cggcgtgggtg gctgctgcag gttgcacact	840
10	gggccacaga ggatccagca aggatgaaga aatggagcag cacagacttg ggggcagctg	900
	cggaccact ccaaaaggac acctgcccag accccttgga tggagacct aactccaggc	960
	cacctccagc caagccccag ctctccacgg ccaagagccg caccggctc tttgggaagg	1020
	gtgactcgga ggaggcttcc cgggtggatt gcctcacga ggaaggtgag ctggactcct	1080
15	gcccacat cactgacgc cctgttatca ccatccagag gccaggagac ggccccaccg	1140
	gtgccagggt gctgtcccag gactctgtcg ccgccagcac cgagaagacc ctcaggctct	1200
	atgatcgag gagtattctt gaagcgttg ctcaagaataa ctgccaggat ctggagagcc	1260
	tgctgctctt cctgcagaag agcaagaagc acctcacaga caacgagttc aaagacctg	1320
20	agacagggaa gacctgtctg ctgaaagcca tgcctaacct gcacgacgga cagaacacca	1380
	ccatccccct gctcctggag atcgcgcggc aaacggacag cctgaaggag cttgtcaacg	1440
	ccagctacac ggacagctac tacaagggcc agacagcact gcacatcgcc atcgagagac	1500
	gcaacatggc cctggtgacc ctctgggtgg agaacggagc agacgtccag gctgcggccc	1560
25	atggggactt ctttaagaaa accaaagggc ggccctggat ctacttcggt gaactgcccc	1620
	tgtccctggc cgcgtgcacc aaccagctgg gcacgtgaa gtctctgctg cagaactcct	1680
	ggcagacggc cgacatcagc gccagggact cgggtgggcaa cacggtgctg cacgccctgg	1740
	tggagggtggc cgacaacacg gccgacaaca cgaagtctgt gacgagcatg tacaatgaga	1800
30	ttctgacctt gggggccaaa ctgcaccgga cgtgaagct ggaggagctc accaacaaga	1860
	agggaatgac gccgctggct ctggcagctg ggaccgggaa gatcggggctc ttggcctata	1920
	ttctccagcg ggagatccag gagcccaggt gcaggcacct gtccagggaag ttcaccgagt	1980
	gggcctacgg gcccgtcac tctctgctgt acgacctgtc ctgcatcgac acctgcgaga	2040
35	agaactcggg gctggagggt atcgctaca gcagcagcga gaacctaat cgccacgaca	2100
	tgtctctggt ggagccgctg aaccgactcc tgcaggacaa gtgggacaga ttctgcaagc	2160
	gcatcttcta ctcaacttc ctggtctaact gcctgtacat gatcatcttc accatggctg	2220
	cctactacag gcccgtagat ggcttgctc cctttaagat ggaaaaaact ggagactatt	2280
40	tccgagttac tggagagatc ctgtctgtgt taggaggagt ctacttcttt tccgagggga	2340
	ttcagtatct cctgcagagg cggccgtcga tgaagacct gtctgtggac agctacagtg	2400
	agatgctttt cttctgcag tcaactgttca tgcgtggcac cgtggtgctg tacttcagcc	2460
	acctcaagga gtatgtggct tccatgggat tctccctggc cttgggctgg accaactgac	2520
45	tctactacac ccgcggttcc cagcagatcg gcatctatgc cgtcatgata gagaagatga	2580
	tcttgagaga cctgtgccgt ttcatgtttg tctacgtcgt cttctgttcc gggttttcca	2640
	cagcgggtgt gacgctgatt gaagacggga agaagtactc cctgccgtct gactccacgt	2700
	cgcacagggt gcgggggacct gctgcaggc ccccgatag ctctacaac agcctgtact	2760
	ccacctgcct ggagctgttc aagttcacca tcggcatggg cgacctggag ttcactgaga	2820
50	actatgactt caaggctgtc ttcatcatcc tgcgtgtggc ctatgtaatt ctcacctaca	2880
	tctctctgct caacatgtcc atcgccctca tgggtgagac tgtcaacaag atcgcacagg	2940
	agagcaagaa catctggaag ctgcagagag ccataccat cctggacacg gagaagagct	3000

55



EP 0 943 683 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

tccttaagtg catgaggaag gccttccgct caggcaagct gctgcagggtg gggtagacacac 3060  
ctgatggcaa ggaagactac cgggtggtgct tcagggtgga cgaggtgaac tggaccacct 3120  
ggaacaccaa cgtgggcata atcaacgaag acccgggcaa ctgtgagggc gtcaagcgca 3180  
ccctgagctt ctccctgcgg tcaagcagag ttccaggcag acactggaag aactttgccc 3240  
tgggtccccc tttaagagag gcaagtgtc gagataggca gtctgtcag cccgaggaag 3300  
tttatctgag acagttttca ggggtctctga agccagagga cgtgaggtc ttcaagagtc 3360  
ctgccgtctc cggggagaag tgaggacgtc acgcagacag cactgtcaac actgggcctt 3420  
aggagacccc gttgccacgg ggggctgctg agggaaacacc agtgctctgt cagcagcctg 3480  
gcctggtctg tgccctgcca 3500

15  
20

<210> 8  
<211> 839  
<212> PRT  
<213> Homo sapiens

20  
25  
30  
35  
40  
45  
50  
55

<400> 8  
Met Lys Lys Trp Ser Ser Thr Asp Leu Gly Ala Ala Ala Asp Pro Leu  
1 5 10 15  
Gln Lys Asp Thr Cys Pro Asp Pro Leu Asp Gly Asp Pro Asn Ser Arg  
20 25 30  
Pro Pro Pro Ala Lys Pro Gln Leu Ser Thr Ala Lys Ser Arg Thr Arg  
35 40 45  
Leu Phe Gly Lys Gly Asp Ser Glu Glu Ala Phe Pro Val Asp Cys Pro  
50 55 60  
His Glu Glu Gly Glu Leu Asp Ser Cys Pro Thr Ile Thr Val Ser Pro  
65 70 75 80  
Val Ile Thr Ile Gln Arg Pro Gly Asp Gly Pro Thr Gly Ala Arg Leu  
85 90 95  
Leu Ser Gln Asp Ser Val Ala Ala Ser Thr Glu Lys Thr Leu Arg Leu  
100 105 110  
Tyr Asp Arg Arg Ser Ile Phe Glu Ala Val Ala Gln Asn Asn Cys Gln  
115 120 125  
Asp Leu Glu Ser Leu Leu Leu Phe Leu Gln Lys Ser Lys Lys His Leu  
130 135 140  
Thr Asp Asn Glu Phe Lys Asp Pro Glu Thr Gly Lys Thr Cys Leu Leu  
145 150 155 160  
Lys Ala Met Leu Asn Leu His Asp Gly Gln Asn Thr Thr Ile Pro Leu  
165 170 175  
Leu Leu Glu Ile Ala Arg Gln Thr Asp Ser Leu Lys Glu Leu Val Asn  
180 185 190  
Ala Ser Tyr Thr Asp Ser Tyr Tyr Lys Gly Gln Thr Ala Leu His Ile  
195 200 205

Ala Ile Glu Arg Arg Asn Met Ala Leu Val Thr Leu Leu Val Glu Asn  
 210 215 220  
 5 Gly Ala Asp Val Gln Ala Ala Ala His Gly Asp Phe Phe Lys Lys Thr  
 225 230 235 240  
 Lys Gly Arg Pro Gly Phe Tyr Phe Gly Glu Leu Pro Leu Ser Leu Ala  
 245 250 255  
 10 Ala Cys Thr Asn Gln Leu Gly Ile Val Lys Phe Leu Leu Gln Asn Ser  
 260 265 270  
 Trp Gln Thr Ala Asp Ile Ser Ala Arg Asp Ser Val Gly Asn Thr Val  
 275 280 285  
 15 Leu His Ala Leu Val Glu Val Ala Asp Asn Thr Ala Asp Asn Thr Lys  
 290 295 300  
 Phe Val Thr Ser Met Tyr Asn Glu Ile Leu Ile Leu Gly Ala Lys Leu  
 305 310 315 320  
 20 His Pro Thr Leu Lys Leu Glu Glu Leu Thr Asn Lys Lys Gly Met Thr  
 325 330 335  
 Pro Leu Ala Leu Ala Ala Gly Thr Gly Lys Ile Gly Val Leu Ala Tyr  
 340 345 350  
 25 Ile Leu Gln Arg Glu Ile Gln Glu Pro Glu Cys Arg His Leu Ser Arg  
 355 360 365  
 Lys Phe Thr Glu Trp Ala Tyr Gly Pro Val His Ser Ser Leu Tyr Asp  
 370 375 380  
 30 Leu Ser Cys Ile Asp Thr Cys Glu Lys Asn Ser Val Leu Glu Val Ile  
 385 390 395 400  
 Ala Tyr Ser Ser Ser Glu Thr Pro Asn Arg His Asp Met Leu Leu Val  
 405 410 415  
 35 Glu Pro Leu Asn Arg Leu Leu Gln Asp Lys Trp Asp Arg Phe Val Lys  
 420 425 430  
 Arg Ile Phe Tyr Phe Asn Phe Leu Val Tyr Cys Leu Tyr Met Ile Ile  
 435 440 445  
 40 Phe Thr Met Ala Ala Tyr Tyr Arg Pro Val Asp Gly Leu Pro Pro Phe  
 450 455 460  
 Lys Met Glu Lys Thr Gly Asp Tyr Phe Arg Val Thr Gly Glu Ile Leu  
 465 470 475 480  
 45 Ser Val Leu Gly Gly Val Tyr Phe Phe Phe Arg Gly Ile Gln Tyr Phe  
 485 490 495  
 Leu Gln Arg Arg Pro Ser Met Lys Thr Leu Phe Val Asp Ser Tyr Ser  
 500 505 510  
 50 Glu Met Leu Phe Phe Leu Gln Ser Leu Phe Met Leu Ala Thr Val Val  
 515 520 525  
 Leu Tyr Phe Ser His Leu Lys Glu Tyr Val Ala Ser Met Val Phe Ser  
 530 535 540

Leu Ala Leu Gly Trp Thr Asn Met Leu Tyr Tyr Thr Arg Gly Phe Gln  
 545 550 555 560  
 5 Gln Met Gly Ile Tyr Ala Val Met Ile Glu Lys Met Ile Leu Arg Asp  
 565 570 575  
 Leu Cys Arg Phe Met Phe Val Tyr Val Val Phe Leu Phe Gly Phe Ser  
 580 585 590  
 10 Thr Ala Val Val Thr Leu Ile Glu Asp Gly Lys Asn Asp Ser Leu Pro  
 595 600 605  
 Ser Glu Ser Thr Ser His Arg Trp Arg Gly Pro Ala Cys Arg Pro Pro  
 610 615 620  
 15 Asp Ser Ser Tyr Asn Ser Leu Tyr Ser Thr Cys Leu Glu Leu Phe Lys  
 625 630 635 640  
 Phe Thr Ile Gly Met Gly Asp Leu Glu Phe Thr Glu Asn Tyr Asp Phe  
 20 645 650 655  
 Lys Ala Val Phe Ile Ile Leu Leu Leu Ala Tyr Val Ile Leu Thr Tyr  
 660 665 670  
 Ile Leu Leu Leu Asn Met Leu Ile Ala Leu Met Gly Glu Thr Val Asn  
 25 675 680 685  
 Lys Ile Ala Gln Glu Ser Lys Asn Ile Trp Lys Leu Gln Arg Ala Ile  
 690 695 700  
 30 Thr Ile Leu Asp Thr Glu Lys Ser Phe Leu Lys Cys Met Arg Lys Ala  
 705 710 715 720  
 Phe Arg Ser Gly Lys Leu Leu Gln Val Gly Tyr Thr Pro Asp Gly Lys  
 725 730 735  
 35 Asp Asp Tyr Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp Thr Thr  
 740 745 750  
 Trp Asn Thr Asn Val Gly Ile Ile Asn Glu Asp Pro Gly Asn Cys Glu  
 755 760 765  
 40 Gly Val Lys Arg Thr Leu Ser Phe Ser Leu Arg Ser Ser Arg Val Ser  
 770 775 780  
 Gly Arg His Trp Lys Asn Phe Ala Leu Val Pro Leu Leu Arg Glu Ala  
 785 790 795 800  
 45 Ser Ala Arg Asp Arg Gln Ser Ala Gln Pro Glu Glu Val Tyr Leu Arg  
 805 810 815  
 Gln Phe Ser Gly Ser Leu Lys Pro Glu Asp Ala Glu Val Phe Lys Ser  
 50 820 825 830  
 Pro Ala Ala Ser Gly Glu Lys  
 835

55

## Claims

1. An isolated polypeptide comprising an amino acid sequence which has at least 90% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, over the entire length of SEQ ID NO:2 or SEQ ID NO:8, respectively.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8.
4. The isolated polypeptide of SEQ ID NO:2 or SEQ ID NO:8.
5. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 90% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, over the entire length of SEQ ID NO:2 or SEQ ID NO:8, respectively; or a nucleotide sequence complementary to said isolated polynucleotide.
6. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:8, over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
7. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1 or SEQ ID NO:7 over the entire length of SEQ ID NO:1 or SEQ ID NO:7, respectively; or a nucleotide sequence complementary to said isolated polynucleotide.
8. The isolated polynucleotide as claimed in any one of claims 5 to 7 in which the identity is at least 95%.
9. An isolated polynucleotide selected from:
  - (a) a polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:8;
  - (b) the polynucleotide of SEQ ID NO:1 or SEQ ID NO:7; and
  - (c) a polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:7, or a fragment thereof; or a nucleotide sequence complementary to said isolated polynucleotide
10. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.
11. A host cell comprising the expression system of claim 10 or a membrane thereof expressing the polypeptide of claim 1.
12. A process for producing a polypeptide of claim 1 comprising culturing a host cell of claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.
13. An antibody immunospecific for the polypeptide of claim 1.
14. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:
  - (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;
  - (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;
  - (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;
  - (d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or
  - (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and

said polypeptide in cells, using for instance, an ELISA assay.

15. An agonist or antagonist to the polypeptide of claims 1 to 4.

16. A compound which is:

- (a) an agonist or antagonist to the polypeptide of claims 1 to 4;
- (b) isolated polynucleotide of claims 5 to 9; or
- (c) a nucleic acid molecule that modulates the expression of the nucleotide sequence encoding the polypeptide of claim 1;

for use in therapy.

17. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:

- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.

18. An isolated polynucleotide selected from the group consisting of

- (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 85% identity to SEQ ID NO:3 or SEQ ID NO:5, over the entire length of SEQ ID NO:3 or SEQ ID NO:5, respectively;
- (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3 or SEQ ID NO:5;
- (c) the polynucleotide of SEQ ID NO:3 or SEQ ID NO:5; or
- (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 90% identity to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively.

19. A polypeptide selected from the group consisting of

- (a) a polypeptide which comprises an amino acid sequence which has at least 90% identity to that of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively;
- (b) a polypeptide in which the amino acid sequence has at least 90% identity to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, over the entire length of SEQ ID NO:4 or SEQ ID NO:6, respectively;
- (c) a polypeptide which comprises the amino acid of SEQ ID NO:4 or SEQ ID NO:6;
- (d) a polypeptide which is the polypeptide of SEQ ID NO:4 or SEQ ID NO:6; or
- (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3 or SEQ ID NO:5.



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 20 3620 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,X	CATERINA ET AL: "The capsaicin receptor: a heat-activated ion channel in the pain pathway" NATURE, vol. 389, no. 1, 23 October 1997, pages 816-823, XP002915410	1-16,18,19	C12N15/12 C12N15/11 C12N15/85 C12N5/10 C07K14/705 C12Q1/68 G01N33/50 A61K31/70
Y	* page 816-823; figures 1,2,5-7 *	14-17	
Y	US 5 232 684 A (BLUMBERG PETER M ET AL) 3 August 1993 * claims 1-26,30; figures 1,2 *	14-17	
X	DATABASE EMBEST17 HSZZ26689, 18 April 1997 ADAMS ET AL: "Expressed Sequence Tag" XP002107748	9,18,19	
A	* the whole document *	1-8	
E	WO 99 09140 A (BRAKE ANTHONY ;JULIUS DAVID J (US); UNIV CALIFORNIA (US); CATERINA) 25 February 1999 Sequence listings of VR-1 subtype * figures 1-18; examples 5,6 *	6,7,9,16,18,19	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		30 June 1999	van Klompenburg, W
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>3 : member of the same patent family, corresponding document</p>	

EPO FORM 1503 03.82 (P04C07)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number

EP 98 20 3620

As far as claim 17 is directed to a diagnostic method practised on the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

-----

Reason for the limitation of the search:

Claims 15 and 16 could not be searched completely due to the lack of characterization of the claimed subject matter

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 20 3620

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-06-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5232684 A	03-08-1993	NONE	
WO 9909140 A	25-02-1999	AU 9115698 A	08-03-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82